Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/167785
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sequeiros, Tamara | - |
dc.contributor.author | Rigau, Marina | - |
dc.contributor.author | Chiva, Cristina | - |
dc.contributor.author | Montes, Melania | - |
dc.contributor.author | Garcia-Grau, Iolanda | - |
dc.contributor.author | Garcia, Marta | - |
dc.contributor.author | Diaz, Sherley | - |
dc.contributor.author | Celma, Ana | - |
dc.contributor.author | Bijnsdorp, Irene | - |
dc.contributor.author | Campos, Alex | - |
dc.contributor.author | Mauro, Primiano Di | - |
dc.contributor.author | Borrós, Salvador | - |
dc.contributor.author | Reventós Puigjaner, Jaume | - |
dc.contributor.author | Doll, Andreas | - |
dc.contributor.author | Paciucci Barzanti, Rosanna | - |
dc.contributor.author | Pegtel, D. Michiel | - |
dc.contributor.author | Torres, Inés de | - |
dc.contributor.author | Sabidó Aguadé, Eduard | - |
dc.contributor.author | Morote, Juan | - |
dc.contributor.author | Olivan Riera, Mireia | - |
dc.date.accessioned | 2020-07-06T12:00:10Z | - |
dc.date.available | 2020-07-06T12:00:10Z | - |
dc.date.issued | 2017-01-17 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/2445/167785 | - |
dc.description.abstract | Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches-such as selected reaction monitoring (SRM)-as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients. | - |
dc.format.extent | 17 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Impact Journals | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.13634 | - |
dc.relation.ispartof | Oncotarget, 2017, vol. 8, num. 3, p. 4960-4976 | - |
dc.relation.uri | https://doi.org/10.18632/oncotarget.13634 | - |
dc.rights | cc-by (c) Sequeiros, Tamara et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Indicadors biològics | - |
dc.subject.classification | Orina | - |
dc.subject.classification | Càncer de pròstata | - |
dc.subject.other | Indicators (Biology) | - |
dc.subject.other | Urine | - |
dc.subject.other | Prostate cancer | - |
dc.title | Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 697751 | - |
dc.date.updated | 2020-07-06T12:00:10Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/269285/EU//PROTBIOFLUID | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27903962 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Publicacions de projectes de recerca finançats per la UE Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
697751.pdf | 4.89 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License